Takeda’s Combo Duetact Will Launch Later This Year For Type 2 Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda's existing Actos sales force will detail the pioglitazone and glimepiride combination therapy to primary care physicians.
You may also be interested in...
Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
Japanese firm simultaneously announces that it has inked a monoclonal antibody discovery deal with Xoma.
Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
Japanese firm simultaneously announces that it has inked a monoclonal antibody discovery deal with Xoma.
Takeda Discontinues TAK-128 Clinical Program For Peripheral Diabetic Neuropathy
Takeda is discontinuing development of a Phase II compound, TAK-128, for the treatment of peripheral diabetic neuropathy after the candidate failed to show sufficient efficacy to support its continued development, the company reported